Clinical trials are the initial spark that drives the engine of pharmaceutical products; they are critical for demonstrating product success. But we have observed that in rare diseases (like many oncology indications), there is a gap between patient perception of clinical trials and the expectations from trial executors and sponsoring companies.
Many pharma companies are looking to optimise the clinical trial process and improve patient experience and data granularity, and in our partnerships with these companies we have been looking at many angles of a central question: how can technology that is so present in every aspect of life impact the industry’s ability to recruit and retain patients on clinical trials.
Lisa Logan, Vice President and member of OR:BIT (Oncology Research: Business Intelligence Team), has authored a white paper on the subject. Simply contact us for a free download.